The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Teclistamab’s place in the myeloma treatment landscape
Amrita Krishnan
• 15 Dec 2021
Amrita Krishnan, MD, City of Hope, Duarte, CA, shares her insights into advancements in drugs used to treat multiple myeloma. Dr Krishnan draws focus on how treatment options are changing, using bispecific antibodies targeting novel targets such as GPRC5D as an example. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.
